Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?

"Declarations Conflict of InterestS.S.—honoraria from Sandoz/Novartis; Pro.Med.; A.S.—no conflict of interest; M.B.—speakers bureau: Amgen, Daiichi Sankyo, KRKA, Pfizer, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Pfizer, Sanofi-Aventis, Teva, and Zentiva; consultant to Adamed, Amgen, Daiichi Sankyo, Esperion, MSD, NewAmsterdam, Novartis, Novo-Nordisk, and Sanofi-Aventis; Grants from Amgen, Daiichi Sankyo, Viatris, and Sanofi; CMO at the Nomi Biotech Corporation and Dairy Biotechnologies. In addition, M.B. reports the following: President of the International Lipid Expert Panel (ILEP), Secretary of the European Atherosclerosis Society (EAS), and President of the Polish Lipid Association (PoLA). Human and Animal Rights and Informed ConsentThis article does not contain any studies with human or animal subjects performed by any of the authors. Conflict of Interest S.S.—honoraria from Sandoz/Novartis; Pro.Med.; A.S.—no conflict of interest; M.B.—speakers bureau: Amgen, Daiichi Sankyo, KRKA, Pfizer, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Pfizer, Sanofi-Aventis, Teva, and Zentiva; consultant to Adamed, Amgen, Daiichi Sankyo, Esperion, MSD, NewAmsterdam, Novartis, Novo-Nordisk, and Sanofi-Aventis; Grants from Amgen, Daiichi Sankyo, Viatris, and Sanofi; CMO at the Nomi Biotech Corporation and Dairy Biotechnologies. In addition, M.B. reports the following: President of the International Lipid Expert Panel (ILEP), Secretary of the European Atherosclerosis Society (EAS), and President of the Polish Lipid Association (PoLA)."